Published on
Mar 14, 2025
New Findings on Tildrakizumab for Nail Psoriasis, with Paul Yamauchi, MD, PhD
New phase 3b findings presented at the American Academy of Dermatology (AAD) Annual Meeting demonstrated that tildrakizumab-asmn treatment led to significant improvements in moderate-to-severe nail psoriasis versus placebo, as well as a lack of new safety …
Source:
HCPLive
-
Label Pending
